Key result
Injecting a fusion protein between LPL and its transporter GBIHBP1 effectively lowered plasma triglycerides in mice.
Why the study?
Does a fusion protein between LPL and GBIHBP1 lower plasma triglycerides in mice?
Does a fusion protein between LPL and GBIHBP1 lower plasma triglycerides in mice?
A novel LPL-GBIHBP1 fusion protein effectively lowers plasma triglycerides in mice, representing a promising potential approach for treating familial chylomicronemia syndrome.
The enzyme lipoprotein lipase (LPL) is responsible for breaking down triglycerides in the blood. Mutations in LPL cause a rare but debilitating disorder characterized by excessive plasma triglyceride levels for which treatment options are limited. Nimonkar et al. now present a fusion protein between LPL and its physiological transporter GBIHBP1 that is highly active and largely resistant to physiological inhibitors of LPL. Injecting this fusion protein effectively lowers plasma triglycerides in mice and represents a promising new approach for lowering triglycerides in patients with familial chylomicronemia syndrome.
No takes yet. Share an insight, caveat, or question.
Ruppert et al. (2020) studied Familial chylomicronemia syndrome. LPL-GBIHBP1 fusion protein was evaluated on Plasma triglyceride levels. Injecting a fusion protein between LPL and its transporter GBIHBP1 effectively lowered plasma triglycerides in mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: